Comparative Pharmacology
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus MIGERGOT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHYLERGONOVINE MALEATE versus MIGERGOT.
METHYLERGONOVINE MALEATE vs MIGERGOT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ergot alkaloid; partial agonist/antagonist at alpha-adrenergic, serotonin (5-HT2), and dopamine receptors; directly stimulates uterine smooth muscle contractions.
Ergotamine is a partial agonist at serotonin (5-HT) receptors, particularly 5-HT1B/1D, and also exhibits agonism at alpha-adrenergic and dopamine receptors. It causes vasoconstriction of cranial blood vessels and reduces central pain transmission.
0.2 mg intramuscularly or intravenously once, may repeat as needed every 2-4 hours for a maximum of 5 doses.
1 mg ergotamine tartrate and 100 mg caffeine per rectal suppository, inserted rectally at onset of headache; may repeat after 1 hour if needed, maximum 2 suppositories per headache and 5 per week.
None Documented
None Documented
Biphasic: initial (alpha) ~10-30 min; terminal (beta) ~2-3 hours in normal subjects; prolonged to ~6-12 hours in hepatic impairment or pregnancy
Ergotamine: 2 hours (initial) with terminal half-life 21-34 hours due to enterohepatic recirculation; caffeine: 3-6 hours.
Renal (approximately 60-80% as metabolites, <1% unchanged); biliary/fecal (minor route, approximately 20-30%)
Primarily hepatic metabolism (ergotamine) with 90% biliary/fecal elimination as metabolites; less than 4% renal excretion unchanged.
Category D/X
Category C
Ergot Alkaloid
Ergot Alkaloid